Case report on premature hair graying treated with Melitane 5% and oral hair supplements

Sakhiya, Jagdish; Sakhiya, Dhruv; Patel, Mitesh; Daruwala, Feral

doi:10.4103/ijp.ijp_166_19

Cited by 6 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with premature canities, that there was stimulation of melanocyte melanosome biogenesis and eumelanin synthesis in plucked hairs within 3 months 16 . Another α‐melanocyte‐stimulating hormone (α‐MSH) agonist, Melitane is also reported to reverse the premature graying of hair, 79 however, data regarding efficacy is very limited.…”

Section: Resultsmentioning

confidence: 99%

“…23 In cases of vitiligo, the melanocytes are more sensitive to oxidative damage 78 and are more prone to premature graying. 16 Another α-melanocyte-stimulating hormone (α-MSH) agonist, Melitane is also reported to reverse the premature graying of hair, 79 however, data regarding efficacy is very limited.…”

Section: Other Co-morbid Conditions and Occurrence Of Pghmentioning

confidence: 99%

See 1 more Smart Citation

Premature graying of hair: Risk factors, co‐morbid conditions, pharmacotherapy and reversal—A systematic review and meta‐analysis

Mahendiratta

Sarma

Kaur

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Premature graying of hair (PGH) being a very common entity for which pharmacotherapy and reversibility are not properly addressed. Therefore, this systematic review was conducted to address these issues. For this relevant study were selected from various databases including PubMed, EMBASE, OVID, Web of science, Scopus, and Google Scholar till January 20, 2019. Studies which reported risk factors, co-morbid conditions associated with PGH, its pharmacotherapy and reversal were included in the study. Although many risk factors are reported in literature, smoking, vitamin deficiency (B12, folic acid, and B7), mineral deficiency (low serum calcium and serum ferritin) are found to be associated with PGH. Other important risk factors are family history of PGH, obesity, high B.P, lack of exercise, drugs, genetic syndromes, dyslipidemia, thyroid disorders, hyperuricemia, and alteration in liver function. PGH is found to be an important marker of CAD, more so in case of smoker. Among different pharmacotherapeutic management options, low grade recommendation (2A) is given to calcium pantothenate, PABA, calcium pantothenate + PABA combination. Anu-tailam is the only herbal agent evaluated in clinical research settings. Finally, treating the accompanying pathologies led to the reversal of the disease in many cases. K E Y W O R D S co-morbidities, premature graying of hair, reversal, risk factors, treatment 1 | INTRODUCTION Hair graying is a part of aging, which typically starts around 34.2 ± 9.6 years (whites) to 43.9 ± 10.3 years (in blacks). 1 Premature graying of hair (PGH) is said to occur if hair graying starts before the age of 20 (Caucasians) and 30 years in Africans. 1-4 For Indian people, a cut off range of 25 years is suggested. 1,5 DOPA oxidase positive follicular melanocytes are the primary site of pigment production. Hair color basically depends on the eumelanin Abbreviations: BMD, bone mineral density; BMI, body mass index; CAD, coronary artery disease; DBP, diastolic blood pressure; FBS, fasting blood sugar; OR, odds ratio; PABA, paraamino benzoic acid; PGH, premature graying of hair; RCT, randomized controlled trials; SBP, systolic blood pressure; TERT, telomerase reverse transcriptase. Saniya Mahendiratta and Phulen Sarma have contributed equally to this study and both are considered as first authors.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Other Co-morbid Conditions and Occurrence Of Pghmentioning

confidence: 99%

Premature graying of hair: Risk factors, co‐morbid conditions, pharmacotherapy and reversal—A systematic review and meta‐analysis

Mahendiratta

Sarma

Kaur

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…We envision this self-assembling strategy would lead to a successful drug like lanreotide. Since skin pigmentation disorders are associated with several diseases, including EPP, premature hair graying, and melanoma, this selective, potent MC1R agonist hydrogel is a promising, alternative approach for the treatment or prevention of these diseases. , …”

Section: Discussionmentioning

confidence: 99%

MC1R Peptide Agonist Self-Assembles into a Hydrogel That Promotes Skin Pigmentation for Treating Vitiligo

Zhu

Wang

et al. 2023

ACS Nano

View full text Add to dashboard Cite

Vitiligo, a common skin disease that seriously affects 0.5−2.0% of the worldwide population, lacks approved therapeutics due to a wide range of adverse side effects. As a key regulator of skin pigmentation, MC1R may be an effective therapeutic target for vitiligo. Herein, we report an MC1R peptide agonist that directly self-assembles into nanofibrils that form a hydrogel matrix under normal physiological conditions. This hydrogel exhibits higher stability than free peptides, sustained release, rapid recovery from shear-thinning, and resistance to enzymatic proteolysis. Furthermore, this peptidal MC1R agonist upregulates tyrosinase, tyrosinase-related protein-1 (TYRP-1), and tyrosinase-related protein-2 (TYRP-2) to stimulate melanin synthesis. More importantly, MC1R agonist hydrogel promotes skin pigmentation in mice more potently than free MC1R agonist. This study supports the development of this MC1R agonist hydrogel as a promising pharmacological intervention for vitiligo.

show abstract

“…[27] Sakhiya et al reported repigmentation of gray hair following the use of 5 % melitane. [28] Melitane is a biomimetic peptide, agonist of alpha-MSH. It acts through binding melanocortin 1 receptor and thus stimulating the process of melanogenesis in hair.…”

Section: Investigationsmentioning

confidence: 99%

Premature graying of hair: A concise review

Singh

Madke

Bansod³

et al. 2021

CSDM

View full text Add to dashboard Cite

Authors have attempted to provide a short concise and clinically relevant review on premature graying of hairs with the focus of updated pathogenesis, rational investigations, and treatment options. Premature graying of hairs is a fairly common clinical condition faced by dermatologists, however, very scarce therapeutic options are available for successful management of gray hairs. The role of antioxidants is not yet established firmly in the therapeutic armamentarium of premature graying of hairs. Authors have summarized the currently available therapeutic options for the treatment of premature graying of hairs.

show abstract

Case report on premature hair graying treated with Melitane 5% and oral hair supplements

Cited by 6 publications

References 8 publications

Premature graying of hair: Risk factors, co‐morbid conditions, pharmacotherapy and reversal—A systematic review and meta‐analysis

Premature graying of hair: Risk factors, co‐morbid conditions, pharmacotherapy and reversal—A systematic review and meta‐analysis

MC1R Peptide Agonist Self-Assembles into a Hydrogel That Promotes Skin Pigmentation for Treating Vitiligo

Premature graying of hair: A concise review

Contact Info

Product

Resources

About